Hitachi Rail is modernising the Jakarta Metro’s Automatic Fare Collection (AFC) system

Hitachi revised its fiscal year 2026 outlook, lowering sales guidance to $73.125 billion from $74.000 billion, a decrease of $875 million, while keeping a GAAP EPS target of $1.26. The article also cites Q1 results of $0.27 GAAP EPS versus a $0.22 estimate, with sales up to $17.002 billion.

Hitachi reported Q1 EPS of $0.27, above the $0.22 analyst estimate, while sales rose 8.83% year over year to $17.002 billion. However, EPS fell 53.45% versus $0.58 a year earlier, indicating weaker profitability despite revenue growth. The article also notes Hitachi Vantara’s Norman site was named a WEF Global Lighthouse Factory.

Tesla launched its Cybercab, an autonomous vehicle without steering wheels or pedals, in Austin. Public rides began Friday, adding to its Robotaxi fleet. Competitors like Zoox, Uber, Wayve, and Waymo are expanding their autonomous services, with Waymo leading in U.S. city presence. Tesla's strategy relies on vertical integration and camera-only self-driving tech, but its success is uncertain.

JFrog (FROG) shares fell 4.5% in two sessions and 11.3% for the week, closing at $87.60. Analysts remain bullish, with Cantor Fitzgerald setting a $115 target and Bank of America citing AI-driven growth potential. The company's market cap is $10.8B. 22 analysts recommend buying, 3 are neutral.

Moderna and Merck's successful Phase 3 trial for a personalized mRNA melanoma vaccine has renewed optimism in cancer vaccine development. Experts hope this success will reduce public skepticism and attract more investment. The mRNA technology, previously used in COVID-19 vaccines, is seen as promising for cancer treatment, with potential applications in other cancers as well.

Atrium Therapeutics (RNA) reported Q2 2026 results, highlighting FDA clearance for ATR 1072 and a $15M milestone payment from Bristol Myers Squibb. The company has $263.9M in cash, enough to fund operations through mid-2028. However, expenses outpaced revenue, with $25.6M in costs against $3M in collaboration revenue. Clinical trials are in early stages, with data expected in H2 2027.